<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; sight</title>
	<atom:link href="http://www.tapanray.in/tag/sight/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Astronomical Prices of Patented Cancer Drugs: A Solution in Sight?</title>
		<link>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight</link>
		<comments>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/#comments</comments>
		<pubDate>Thu, 20 Feb 2014 13:25:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[astronomical]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmaco-economics]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reserachers]]></category>
		<category><![CDATA[sight]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5014</guid>
		<description><![CDATA[Astronomical prices of patented anti-cancer dugs have become a subject of great concern not just in India. It is becoming an issue across the world. After issuing the first ever Compulsory License (CL) for Nexavar of Bayer in India, the &#8230; <a href="http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
